Psycho-Babble Medication Thread 9332

Shown: posts 1 to 9 of 9. This is the beginning of the thread.

 

reboxetine

Posted by Stephanie La Fortune on July 29, 1999, at 11:54:13

Can I obtain reboxetine in Mexico?

 

Re: reboxetine

Posted by Carolyn on July 29, 1999, at 17:55:31

In reply to reboxetine, posted by Stephanie La Fortune on July 29, 1999, at 11:54:13

> Can I obtain reboxetine in Mexico?

What is it? Just curious! Thanks!

 

Re: reboxetine

Posted by Not A. Medico on July 30, 1999, at 18:20:13

In reply to Re: reboxetine, posted by Carolyn on July 29, 1999, at 17:55:31

> > Can I obtain reboxetine in Mexico?
>
> What is it? Just curious! Thanks!

3 URLs you might find helpful, and a PR press release:
==========
http://www.ja-web.com/depression/AntidepressantFocus/Reboxetine.htm
http://www.mhsource.com/edu/psytimes/p980710.html
http://www.dr-bob.org/tips/split/Reboxetine.html
==========
Pharmacia & Upjohn Receives FDA 'Approvable' Letter for VESTRA(TM)

BRIDGEWATER, N.J., July 30 /PRNewswire/ -- Pharmacia & Upjohn (NYSE: PNU) is pleased to announce that the U.S. Food and Drug Administration (FDA) late yesterday issued an "approvable letter" for the company's antidepressant, VESTRA(TM) (reboxetine mesylate tablets). Pharmacia & Upjohn will continue to work with the FDA to secure final approval for VESTRA and anticipates a fourth quarter launch in the United States.

As previously announced, Pharmacia & Upjohn has entered into an agreement with Janssen Pharmaceutica to co-promote VESTRA in the United States. Under terms of the agreement, Janssen, a wholly owned subsidiary of Johnson & Johnson, will promote VESTRA to psychiatrists in the U.S. following market clearance by the FDA. Pharmacia & Upjohn will be responsible for promotion to primary care physicians in the United States.

VESTRA is currently marketed by Pharmacia & Upjohn as EDRONAX(TM) and NOREBOX(TM) in countries outside the United States.

Pharmacia & Upjohn is a global, innovation-driven pharmaceutical and health care company. Pharmacia & Upjohn's products, services and employees demonstrate its commitment to improve wellness and quality of life for people around the world.

Pharmacia & Upjohn Patient Product Services Hotline: 888-691-6813

Pharmacia & Upjohn Physician/Pharmacist Hotline: 800-253-8600 ext. 3-8244

SOURCE Pharmacia & Upjohn Inc.

CO: Pharmacia & Upjohn Inc.

ST: New Jersey

IN: MTC HEA

SU:

07/30/99 09:30 EDT http://www.prnewswire.com

 

Re: reboxetine

Posted by kris on July 31, 1999, at 23:38:48

In reply to Re: reboxetine, posted by Not A. Medico on July 30, 1999, at 18:20:13

so when exactly will it be available??? One month? One year?

> > > Can I obtain reboxetine in Mexico?
> >
> > What is it? Just curious! Thanks!
>
> 3 URLs you might find helpful, and a PR press release:
> ==========
> http://www.ja-web.com/depression/AntidepressantFocus/Reboxetine.htm
> http://www.mhsource.com/edu/psytimes/p980710.html
> http://www.dr-bob.org/tips/split/Reboxetine.html
> ==========
> Pharmacia & Upjohn Receives FDA 'Approvable' Letter for VESTRA(TM)
>
> BRIDGEWATER, N.J., July 30 /PRNewswire/ -- Pharmacia & Upjohn (NYSE: PNU) is pleased to announce that the U.S. Food and Drug Administration (FDA) late yesterday issued an "approvable letter" for the company's antidepressant, VESTRA(TM) (reboxetine mesylate tablets). Pharmacia & Upjohn will continue to work with the FDA to secure final approval for VESTRA and anticipates a fourth quarter launch in the United States.
>
> As previously announced, Pharmacia & Upjohn has entered into an agreement with Janssen Pharmaceutica to co-promote VESTRA in the United States. Under terms of the agreement, Janssen, a wholly owned subsidiary of Johnson & Johnson, will promote VESTRA to psychiatrists in the U.S. following market clearance by the FDA. Pharmacia & Upjohn will be responsible for promotion to primary care physicians in the United States.
>
> VESTRA is currently marketed by Pharmacia & Upjohn as EDRONAX(TM) and NOREBOX(TM) in countries outside the United States.
>
> Pharmacia & Upjohn is a global, innovation-driven pharmaceutical and health care company. Pharmacia & Upjohn's products, services and employees demonstrate its commitment to improve wellness and quality of life for people around the world.
>
> Pharmacia & Upjohn Patient Product Services Hotline: 888-691-6813
>
> Pharmacia & Upjohn Physician/Pharmacist Hotline: 800-253-8600 ext. 3-8244
>
> SOURCE Pharmacia & Upjohn Inc.
>
> CO: Pharmacia & Upjohn Inc.
>
> ST: New Jersey
>
> IN: MTC HEA
>
> SU:
>
> 07/30/99 09:30 EDT http://www.prnewswire.com

 

Re: reboxetine

Posted by Keith Little on December 6, 1999, at 19:38:24

In reply to Re: reboxetine, posted by Not A. Medico on July 30, 1999, at 18:20:13

> > > Can I obtain reboxetine in Mexico?
> >
> > What is it? Just curious! Thanks!
>
> 3 URLs you might find helpful, and a PR press release:
> ==========
> http://www.ja-web.com/depression/AntidepressantFocus/Reboxetine.htm
> http://www.mhsource.com/edu/psytimes/p980710.html
> http://www.dr-bob.org/tips/split/Reboxetine.html
> ==========
> Pharmacia & Upjohn Receives FDA 'Approvable' Letter for VESTRA(TM)
>
> BRIDGEWATER, N.J., July 30 /PRNewswire/ -- Pharmacia & Upjohn (NYSE: PNU) is pleased to announce that the U.S. Food and Drug Administration (FDA) late yesterday issued an "approvable letter" for the company's antidepressant, VESTRA(TM) (reboxetine mesylate tablets). Pharmacia & Upjohn will continue to work with the FDA to secure final approval for VESTRA and anticipates a fourth quarter launch in the United States.
>
> As previously announced, Pharmacia & Upjohn has entered into an agreement with Janssen Pharmaceutica to co-promote VESTRA in the United States. Under terms of the agreement, Janssen, a wholly owned subsidiary of Johnson & Johnson, will promote VESTRA to psychiatrists in the U.S. following market clearance by the FDA. Pharmacia & Upjohn will be responsible for promotion to primary care physicians in the United States.
>
> VESTRA is currently marketed by Pharmacia & Upjohn as EDRONAX(TM) and NOREBOX(TM) in countries outside the United States.
>
> Pharmacia & Upjohn is a global, innovation-driven pharmaceutical and health care company. Pharmacia & Upjohn's products, services and employees demonstrate its commitment to improve wellness and quality of life for people around the world.
>
> Pharmacia & Upjohn Patient Product Services Hotline: 888-691-6813
>
> Pharmacia & Upjohn Physician/Pharmacist Hotline: 800-253-8600 ext. 3-8244
>
> SOURCE Pharmacia & Upjohn Inc.
>
> CO: Pharmacia & Upjohn Inc.
>
> ST: New Jersey
>
> IN: MTC HEA
>
> SU:
>
> 07/30/99 09:30 EDT http://www.prnewswire.com

 

Re: reboxetine: switching from Moclobemide

Posted by Anna P. on December 10, 1999, at 10:19:14

In reply to Re: reboxetine, posted by Keith Little on December 6, 1999, at 19:38:24

> > >I have a question and I need help. I recently got Reboxetine from IAS. I know
its daily dosage is 4mg. I have severe depression, and developed
the tolerance to most of the antidepressants. By joining this board I found there are more people like me. My problem is I respond to medications very quickly, and loose the response within a few weeks. This is my typical pattern.
I'm under care of the psychopharmacologist from another state, but
I can see him only few times a year. Doctors where I live never heard about this king of "phenomena"
I have, and the tolerance.
My question is How safe is to switch from Moclobemide to Reboxetine
knowing these two interact with each other?
I recently added Mirapex to Moclobemide, but I don't feel good on Mirapex. Moclobemide won't do anything by itself even on maximum dozes. I tried to add Ritalin, Dexedrine, Cytomel or Revia to it, as well as Lamictal
with no success.
Please help.
Anna P.

 

Re: reboxetine: switching from Moclobemide

Posted by jamie on December 10, 1999, at 13:14:22

In reply to Re: reboxetine: switching from Moclobemide, posted by Anna P. on December 10, 1999, at 10:19:14


Anna, the cool thing about moclobemide is it only has a two day wash out period. You can start an ssri a mere two days after quitting, and I'm sure reboxetine would be even safer since there's no serotonin syndrome risk. Moclobemide might be lacking in other areas, but its quick wash out period is a nice feature. Don't know anything about mirapex though.

 

Re: reboxetine: switching from Moclobemide

Posted by andrewb on December 11, 1999, at 10:08:36

In reply to Re: reboxetine: switching from Moclobemide, posted by Anna P. on December 10, 1999, at 10:19:14

Anna,

The daily dosage for reboxetine is 8-12 mgs.not 4 mgs.
Why didn't you feel well on Mirapex? I've read that nausea is a common side effect but it disappears in a few weeks.

 

Re: reboxetine: switching from Moclobemide

Posted by Anna P. on December 15, 1999, at 16:13:04

In reply to Re: reboxetine: switching from Moclobemide, posted by andrewb on December 11, 1999, at 10:08:36

> Thank You for replying. I've already adjusted to Mirapex, and it
helped, but I don't have such a good confidence and concentration
like on Wellbutrin or SSRI's. For now, I will stay on Moclobemide and Mirapex combo,as it prevents me from severe depression, and also helped me to avoid Lithium.

Anna


This is the end of the thread.


Show another thread

URL of post in thread:


Psycho-Babble Medication | Extras | FAQ


[dr. bob] Dr. Bob is Robert Hsiung, MD, bob@dr-bob.org

Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.